Kades & Cheifetz LLC - ARBUTUS BIOPHARMA CORP ownership

ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 97 filers reported holding ARBUTUS BIOPHARMA CORP in Q3 2023. The put-call ratio across all filers is 0.90 and the average weighting 0.2%.

Quarter-by-quarter ownership
Kades & Cheifetz LLC ownership history of ARBUTUS BIOPHARMA CORP
ValueSharesWeighting
Q3 2023$40,600
-33.0%
20,0000.0%0.03%
-33.3%
Q1 2023$60,600
+30.0%
20,0000.0%0.05%
+23.1%
Q4 2022$46,60020,0000.04%
Other shareholders
ARBUTUS BIOPHARMA CORP shareholders Q3 2023
NameSharesValueWeighting ↓
Foresite Capital Management IV, LLC 3,705,128$10,300,0004.44%
RTW INVESTMENTS, LP 5,666,754$15,754,0000.59%
COWEN AND COMPANY, LLC 926,200$2,575,0000.22%
Hudson Bay Capital Management LP 850,000$2,363,0000.05%
LADENBURG THALMANN FINANCIAL SERVICES INC. 1,774,915$4,934,0000.03%
Point72 Asset Management, L.P. 1,897,284$5,274,0000.03%
683 Capital Management, LLC 77,368$215,0000.02%
Secure Asset Management, LLC 10,000$28,0000.02%
Qube Research & Technologies Ltd 166,138$462,0000.01%
Verition Fund Management LLC 174,455$485,0000.01%
View complete list of ARBUTUS BIOPHARMA CORP shareholders